EYEN Share Price | Eyenovia, Inc. Stock Analysis & Recommendation

Q: Is Eyenovia, Inc. technically bullish or bearish?

As of 11 August 2025, the technical trend for Eyenovia, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance. However, the weekly RSI is bearish, and both the KST and Dow Theory show bearish signals on a monthly basis. The Bollinger Bands reflect a mildly bullish trend weekly but mildly bearish monthly. In terms of performance, Eyenovia has outperformed the S&P 500 over the past week and month, with returns of 2.42% and 64.61% respectively, but has significantly underperformed over the longer term, with a 1-year return of -69.30% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly MACD.

Q: Is Eyenovia, Inc. overvalued or undervalued?

As of 30 March 2023, Eyenovia, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued, particularly given its negative financial metrics. Key ratios include a price-to-book value of -1.45, an EV to EBIT of -0.75, and an EV to EBITDA of -0.78, all indicating significant financial distress.In comparison to its peers, Eyenovia's EV to EBITDA ratio of -0.75 is notably higher than G1 Therapeutics, Inc. at -9.6487 and ADC Therapeutics SA at -4.8904, both of which are classified as risky. The stark contrast in valuation metrics suggests that Eyenovia is not only struggling financially but also lacks the fundamentals to justify its current price of 5.48. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -53.08%, significantly underperforming the S&P 500's 2.44% return.

Q: What does Eyenovia, Inc. do?

Overview: Eyenovia, Inc. is a clinical stage biopharmaceutical company engaged in developing micro-dose therapeutics products in the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market-cap: USD 20.09 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.68 Return on Equity: 305.10% Price to Book: -2.07Contact Details: Address: 295 Madison Ave Ste 2400, NEW YORK NY: 10017 Tel: ['1 813 7669539', '1 646 5367035'] Fax: 1 302 6365454 Website: https://eyenoviabio.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

157.32 k

Shareholding (Mar 2026)

FII

1.38%

Held by 16 FIIs

DII

98.63%

Held by 2 DIIs

Promoter

0.00%

Is Eyenovia, Inc. technically bullish or bearish?

20-Sep-2025

As of August 11, 2025, Eyenovia, Inc. shows a mildly bullish trend driven by daily moving averages and the weekly MACD, despite mixed signals from the RSI and longer-term performance underwhelming compared to the S&P 500.

View full answer

Is Eyenovia, Inc. overvalued or undervalued?

25-Jun-2025

As of March 30, 2023, Eyenovia, Inc. is considered overvalued with negative financial metrics, including a price-to-book value of -1.45 and an EV to EBITDA of -0.78, and has underperformed significantly with a year-to-date return of -53.08%.

View full answer

How big is Eyenovia, Inc.?

22-Jun-2025

As of Jun 18, Eyenovia, Inc. has a market capitalization of 20.09 million, with net sales of 0.06 million and a net profit of -42.37 million over the last four quarters. Shareholder's funds are reported at -13.10 million, and total assets amount to 3.67 million.

View full answer

What does Eyenovia, Inc. do?

22-Jun-2025

Eyenovia, Inc. is a clinical stage biopharmaceutical company focused on developing micro-dose therapeutics. As of March 2025, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $20.09 million.

View full answer

Who are in the management team of Eyenovia, Inc.?

22-Jun-2025

As of March 2022, the management team of Eyenovia, Inc. includes Dr. Fredric Eshelman (Independent Chairman), Dr. Tsontcho Ianchulev (CEO, Director, Chief Medical Officer), and several Independent Directors: Dr. Curt Labelle, Mr. Kenneth Lee, Dr. Ernest Mario, Mr. Charles Mather, and Dr. Anthony Sun. This team oversees the company's strategic direction and operations.

View full answer

Compare Eyenovia, Inc. with Similar Stocks

Kinnate Biopharma, Inc.ADC Therapeutics SA Tiziana Life Sciences Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 6.19% and Operating profit at -1.40% over the last 5 years

With a growth in Net Sales of 1559.45%, the company declared Outstanding results in Mar 26

Risky -

High Institutional Holdings at 28.22%

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 28 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.00

Return on Equity

-23.72%

Price to Book

0.40

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Mar 2026)

Net Profit:

9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.29%

6 Months

-15.42%

1 Year

-62.31%

2 Years

-93.61%

3 Years

43.46%

4 Years

-97.66%

5 Years

-99.22%

Eyenovia, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.19%

EBIT Growth (5y)

-1.40%

EBIT to Interest (avg)

-14.90

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.68

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

28.22%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.40

EV to EBIT

-1.25

EV to EBITDA

-1.27

EV to Capital Employed

0.39

EV to Sales

27.88

PEG Ratio

Dividend Yield

ROCE (Latest)

-31.54%

ROE (Latest)

-23.72%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 9 Schemes (1.75%)

Foreign Institutions

Held by 16 Foreign Institutions (1.38%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 351.43% vs 67.89% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.00",
          "val2": "-3.00",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.60",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.10",
          "val2": "0.10",
          "chgp": "10,000.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8.80",
          "val2": "-3.50",
          "chgp": "351.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-20,635.30%",
          "val2": "-205,889.50%",
          "chgp": "18,525.42%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 700.00% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 9.04% vs -82.42% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "0.10",
          "chgp": "700.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.00",
          "val2": "-31.50",
          "chgp": "39.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "2.50",
          "chgp": "-36.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-33.90",
          "val2": "-14.80",
          "chgp": "-129.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.30",
          "val2": "-49.80",
          "chgp": "9.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-23,334.20%",
          "val2": "-569,724.60%",
          "chgp": "54,639.04%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-5.00

-3.00

-66.67%

Interest

0.20

0.60

-66.67%

Exceptional Items

10.10

0.10

10,000.00%

Consolidate Net Profit

8.80

-3.50

351.43%

Operating Profit Margin (Excl OI)

-20,635.30%

-205,889.50%

18,525.42%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 351.43% vs 67.89% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.80

0.10

700.00%

Operating Profit (PBDIT) excl Other Income

-19.00

-31.50

39.68%

Interest

1.60

2.50

-36.00%

Exceptional Items

-33.90

-14.80

-129.05%

Consolidate Net Profit

-45.30

-49.80

9.04%

Operating Profit Margin (Excl OI)

-23,334.20%

-569,724.60%

54,639.04%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 700.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 9.04% vs -82.42% in Dec 2024

All Annual Results

Company CV

About Eyenovia, Inc.

Eyenovia, Inc.

Pharmaceuticals & Biotechnology

Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of micro-doses therapeutics products utilizing the patented piezo-print delivery technology. Eyenovia’s pipeline is focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. MicroStat is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). MicroPine is topical treatment for progressive myopia, a back-of-the-eye disease. MicroProst is latanoprost formulation product candidate, which is being developed for the reduction of IOP in patients with Chronic Angle Closure Glaucoma (CACG), as well as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product.

Company Coordinates

Company Details

295 Madison Ave Ste 2400 , NEW YORK NY : 10017

Tel: 1 813 76695391 646 5367035

https://eyenoviabio.com/

Registrar Details